Earnings call transcript: InMode Q1 2026 earnings miss despite revenue beat

InMode’s Q1 2026 results were mixed: revenue rose 5% year over year to $82.0 million and beat expectations, but non-GAAP EPS missed at $0.25 versus $0.30 consensus and GAAP gross margin fell to 75% from 78%. The company guided 2026 revenue to $365 million-$375 million and reiterated non-GAAP EPS of $1.33-$1.38, while shares dropped 7.99% premarket. Management said new laser launches, international expansion, and a continued buyback program remain key growth levers, but margin pressure and higher operating expenses remain headwinds.

Analysis

The key read-through is that INMD is transitioning from a pure execution story into a portfolio-quality story: revenue is still growing, but the market is now paying for margin durability rather than top-line momentum. The product mix is the issue, not demand destruction — management is deliberately using lower-margin platforms to widen the addressable procedure set, which should improve customer retention and cross-sell over 12-18 months, but near-term gross margin compression is likely to remain the dominant P&L driver.

The second-order effect is on capital allocation credibility. A company with a net cash balance this large and a sustained buyback program is implicitly signaling that internal growth returns are below prior expectations, yet management is also telegraphing optionality for M&A and potentially dividends. That combination usually supports the stock only when the operating inflection is visible; absent faster proof that the North America reorg and new direct subsidiaries are improving productivity, buybacks risk becoming a velocity-agnostic support rather than a valuation catalyst.

The main catalyst calendar is product/regulatory, not quarterly earnings. The next 2-3 quarters will hinge on whether the new laser launches and China/Argentina execution can offset the structural drag from mix and SG&A. If the FDA timing slips or international direct-subsidiary ramp remains slow, consensus likely has to mark down the 2027 margin path, which is where the stock still looks vulnerable; conversely, any evidence that the U.S. reorg is improving rep productivity would sharply change the debate because the operating leverage is still there if expense growth normalizes.

Contrarian takeaway: the selloff may be more about disappointment versus an elevated preprint setup than a true fundamental break. The market is already discounting weaker profitability, but it may be underappreciating how much embedded optionality exists if management can convert these platforms into a broader one-stop-shop offering. The setup is asymmetric: downside persists as long as margin compression dominates, but upside can re-rate quickly if there is even modest evidence that the restructured sales model is scaling without another step-down in gross margin.

Key Decisions for Investors

• Short INMD on strength over the next 1-3 weeks; target a retrace if the market fades the premarket selloff, with a stop above the post-earnings gap-high. Risk/reward favors the short while the market is still pricing in margin skepticism and before any proof of reacceleration.
• If already structurally bearish on medtech mix pressure, pair long ISRG / short INMD for the next 1-2 quarters. The trade captures quality versus execution risk: ISRG has cleaner margin visibility, while INMD’s valuation is more exposed to gross margin normalization.
• Buy INMD put spreads expiring after the next two catalysts: FDA update on Erbium and the next quarterly print. The best expression is a defined-risk bearish calendar because the stock can bounce on buyback headlines, but the fundamental confirmation window is 60-120 days.
• Do not add to INMD until there is evidence of sequential stabilization in operating margin or rep productivity; use a hard trigger, not a narrative. A cleaner long entry would require proof that North America restructuring is lifting utilization without further gross margin deterioration.
• Watch for a catalyst-driven long only if management comments turn from 'early signs' to measurable KPI improvement in the next quarter; then a tactical long could work for 15-20% upside. Before that, the stock is a patience trade rather than a conviction long.